Dianthus Therapeutics, Inc.
DNTHHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Dianthus Therapeutics, Inc. focuses on Biotechnology services and products. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. With a market capitalization of $4.20B, it sits in mid-cap territory. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Market Cap
$4.20B
Beta
0.18
P/E (TTM)
—
P/E (Fwd)
-16.65
EPS (TTM)
$-4.24
EPS (Fwd)
$-4.61
ROE
-26.1%
ROA
-17.7%
Cash
$886.8M
Total Debt
$1.3M
Free CF
-$92.2M
52W Change
129.1%
Annual Financials
Cash vs Debt
Where DNTH stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DNTH finished 20.09% below its 150-day moving average ($93.28) and 10.43% below its 200-day moving average ($83.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DNTH overbought or oversold?
At the October 20, 2026 close, DNTH's RSI(14) was 18.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $886.8M in cash and $1.3M in debt, DNTH maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$92.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -26.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $6.4M (2022) to $2.0M (2025), a 68% decline worth watching.
With a beta below 0.7, Dianthus Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Dianthus Therapeutics, Inc. and its sector.